Scancell Holdings plc will hold a General Meeting on October 20, 2026, to seek shareholder approval for a share consolidation. Under the proposal, every 10 existing ordinary shares of £0.001 each would become one new consolidated ordinary share of £0.01.
The consolidation relates to the company’s previously announced planned merger with Neuphoria Therapeutics Inc. and its intention to seek a Nasdaq listing. The proposal is intended to facilitate the US listing but is not conditional on it.
If shareholders approve the plan, the new consolidated shares are expected to be admitted to trading on AIM on October 21, 2026.